Create a convertible-note licensing addendum specifying royalty step-downs tied to the spin-off achieving ISO 13485 certification while preserving exclusive antibody IP rights for oncology therapeutics

Generate create a convertible-note licensing addendum specifying royalty step-downs tied to the spin-off achieving iso 13485 certification while preserving exclusive antibody ip rights for oncology therapeutics for Scientific Research and Development Services industry

Scientific Research and Development Services

Agent Configuration

Login required: You need to sign in to execute this agent.

Click to upload or drag and drop

Allowed: PDF, DOCX

Max size: 50MB

Upload the executed convertible note agreement that will serve as the base document for the licensing addendum

Click to upload or drag and drop

Allowed: PDF, DOCX, XLSX, ZIP

Max size: 100MB

Provide comprehensive documentation covering all antibody IP assets including patents, patent applications, sequence listings, and trade secrets
Specify the type and jurisdiction of the spin-off entity that will be subject to ISO 13485 certification requirements
Define the pre- and post-certification royalty framework for oncology therapeutic applications
Specify the exact therapeutic indications and target mechanisms covered under exclusive antibody IP rights
Establish the certification milestone timeline that triggers royalty step-down provisions
Identify any exceptions to exclusivity such as internal research use, diagnostic applications, or companion diagnostics
Specify the legal framework and jurisdiction for this addendum given international IP and medical device considerations
Define ongoing compliance requirements for maintaining royalty step-down benefits beyond ISO 13485 certification
Establish ownership rights for improvements or modifications to antibody IP developed during spin-off operations
Specify conditions under which rights revert or licenses terminate, particularly addressing regulatory setbacks or IP challenges
Set the framework for calculating royalties on sublicensing revenue given regulatory milestone dependencies